Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ModraDoc006/r vs Docetaxel in mCRPC
NCT04028388Phase 2Completed
- Sponsor
- Modra Pharmaceuticals
- Start
- Jul 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of ModraDoc006 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Modra Pharmaceuticals. Started Jul 2019; status: completed.
02
Drugs
ModraDoc006
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04028388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04028388.